All Sections

Site Selection

Facility Planning

Workforce Development

Business+Place

AD Editorial Board

Alan Reeves

Senior Managing Director, Global Strategy, Newmark
Alexandra Segers

General Manager, Tochi Advisors
Amy Gerber

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Bradley Migdal

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Brian Corde

Managing Partner, Atlas Insight
Brian Gallagher

Vice President, Corporate Strategy and Development, PPC Partners, Inc.
Chris Chmura, Ph.D.

CEO & Founder, Chmura Economics
Chris Schwinden

Partner, Site Selection Group
Chris Volney

Managing Director, Americas Consulting, CBRE
Courtland Robinson

Director of Business Development, Brasfield & Gorrie
Courtney Dunbar

Site Selection & Economic Development Leader, Burns & McDonnell
David Hickey

Managing Director, Hickey & Associates
Dennis Cuneo

Former Senior Vice President, Toyota Motor North America; Owner , DC Strategic Advisors
Dianne Jones

Managing Director, Business and Economic Incentives, JLL
Eric Stavriotis

Vice Chairman, CBRE
Joe Dunlap

Chief Supply Chain Officer, Legacy Investing
Lauren Berry

Senior Manager, Location Analysis and Incentives, Maxis Advisors
Marc Beauchamp

President, SCI Global
Matthew Powers

Site Selection Lead, REDI Site Selection
Scott J. Ziance

Partner and Economic Incentives Practice Leader, Vorys, Sater, Seymour and Pease LLP
Scott Kupperman

Founder, Kupperman Location Solutions
Stephen Gray

President & CEO, Gray Construction

AbbVie Expands North Chicago, Illinois, Production Operations

Area Development News Desk

08/13/2025

American pharmaceutical company AbbVie plans to expand its production operations in North Chicago, Illinois. The $195 million project is expected to create at least 50 jobs.

The investment will include the construction of an active pharmaceutical ingredient facility which will expand the company’s chemical synthesis capabilities supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines. Operations are scheduled to begin in fall 2025.

"Over the next decade, AbbVie will expand production of API, drug products, peptides and medical devices in the U.S. to support future medical breakthroughs," said Robert A. Michael, chairman and chief executive officer, AbbVie. "This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients' lives."

The project is being supported by an Economic Development for a Growing Economy (EDGE) agreement with the State.

“This project aligns with the State's vision to attract and retain Illinois companies that are investing in innovation, infrastructure, and workforce development,” noted Illinois Department of Commerce and Economic Opportunity Director Kristin Richards. “We are proud to support businesses like AbbVie that are expanding their operations in Illinois and helping us lead the way in manufacturing.”

AbbVie is a research-based biopharmaceutical company focused on developing and commercializing innovative medicines, known for its work in immunology, oncology, neuroscience, and eye care, among other areas. The company currently operates 11 manufacturing facilities across the U.S.

Project Announcements